The United States Food and Drug Regulatory body recently allowed emergency use of anti-viral investigational vaccine Remdesivir to treat COVID-19 patients.
Highlights
- The USFDA has approved the vaccine after an Indian-American physician, Aruna Subramaninan’s report on Remdesivir.
- According to the report, the vaccine shortened the recovery times of people that have fallen ill due to COVID-19 virus.
- The FDA has provided emergency use authorization of the drug.
Remdesivir
- Remdesivir was developed to treat Ebola virus and Marburg virus.
- However, it was found to be ineffective in treating these diseases.
- International Nonproprietary Name
- Remdesivir is an International Nonproprietary Name (INN).
- The INN is provided to a pharmaceutical drug or active ingredient.
- The INN is issued in Latin, English, Russian, French, Spanish, Chinese and Arabic.
Emergency Use Authorization
- The Emergency Use Authorization in the United States to approve drugs during emergency.
- Earlier, the US FDA had approved use of diagnostic and therapeutic tools to identify and respond 2009 swine flu outbreak.
- In 2013, the FDA issued Emergency Authorization Use of CDC Human Influenza virus.
Remdesivir trial by WHO
- WHO had launched 4 mega trials to treat COVID-19.
- It includes Remdesivir, HCQ (Hydroxychloroquine), combination of Lopinavir and Ritonavir and Interferon-beta along with the combination of Lopinavir and Ritonavir.
No comments:
Post a Comment